Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Authors:
Open Access
- 20 April 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10
Abstract
In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the stage of liver fibrosis is associated with an increased risk of severe liver-related and cardiovascular events and is the strongest predictor of mortality in MAFLD patients. More and more people believe that MAFLD is a multifactorial disease with multiple pathways are involved in promoting the progression of liver fibrosis. Numerous drug targets and drugs have been explored for various anti-fibrosis pathways. The treatment of single medicines is brutal to obtain satisfactory results, so the strategies of multi-drug combination therapies have attracted increasing attention. In this review, we discuss the mechanism of MAFLD-related liver fibrosis and its regression, summarize the current intervention and treatment methods for this disease, and focus on the analysis of drug combination strategies for MAFLD and its subsequent liver fibrosis in recent years to explore safer and more effective multi-drug combination therapy strategies.Keywords
Funding Information
- National Natural Science Foundation of China (81902431, 82270599)
- Natural Science Foundation of Heilongjiang Province (LH2022H018)
- Beijing Xisike Clinical Oncology Research Foundation (Y-Young2022-0188)
- Science Fund for Distinguished Young Scholars of Xinjiang Autonomous Region (XJ2020012)
This publication has 90 references indexed in Scilit:
- Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related CirrhosisTransplantation, 2017
- NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in miceJournal of Hepatology, 2017
- Regression of Liver FibrosisSeminars in Liver Disease, 2017
- Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversalGut, 2017
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes MellitusAnnals of Internal Medicine, 2016
- Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infectionsOncotarget, 2016
- Pathogenesis of nonalcoholic steatohepatitisCellular and Molecular Life Sciences, 2016
- Fibrosis — A Common Pathway to Organ Injury and FailureNew England Journal of Medicine, 2015
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- Structural Mechanism for Statin Inhibition of HMG-CoA ReductaseScience, 2001